Minnesota employers are facing significant challenges as glp1 coverage for both weight loss and diabetes remains stalled at 36% in 2026, despite increasing demand and clinical promise. This trend, highlighted in a recent survey by the International Foundation of Employee Benefit Plans, reveals Minnesota following the national plateau in providing comprehensive access to these medications through employer health plans.

Rise in Demand for GLP-1 Drugs

Across the United States, particularly in regions like Minnesota, the use of glp1 drugs for weight loss has shown a dramatic increase. Between 2024 and 2026, adult usage rates have soared from 3% to 11%. This uptick points to a growing demand for effective weight management options and the mounting expectation that employers will support these medical needs through insurance coverage.

Coverage Differences: Diabetes Versus Weight Loss

While approximately 60% of corporate employers, including those in Minnesota, now cover GLP-1 medications for diabetes medication needs, relatively few extend this benefit to weight loss coverage. Larger employers are more likely than smaller businesses to include weight management in their plans, deepening disparities in pharmacy benefits across the workforce.

Cost Pressures on Employer Health Plans

The surge in demand for GLP-1 medications has presented complex challenges regarding drug cost. Employers in Minnesota are witnessing a strain on pharmacy benefits spending due to increased prescriptions and the high list price of medications. Additional factors such as rebate variations and direct-purchase offers from pharmaceutical companies introduce further complications for plan administrators.

Utilization Controls: Criteria and Authorization

To manage rising expenses, many Minnesota employers require members to meet strict usage criteria—most notably, BMI thresholds—and to complete prior authorization processes before receiving GLP-1 drugs. These protocols are meant to ensure that only those who medically qualify can access the medications under their employer health plans.

Evaluating the Clinical Evidence and Benefits

Despite limitations on insurance coverage, multiple studies underscore the significant weight loss and cardiovascular improvements provided by GLP-1 drugs. Such clinical evidence has prompted growing pressure on employers to consider broader coverage. However, balancing these medical advantages with the realities of escalating drug cost and benefit sustainability remains an ongoing challenge.

Alternative Approaches and Plan Disparities

In some instances, Minnesota employers have referred employees to direct-to-consumer platforms or tax-advantaged accounts if their traditional pharmacy benefits do not support GLP-1 prescriptions for weight management. These alternative options can help bridge access gaps but often shift more responsibility to individuals, especially those at smaller firms where benefits are less robust.

Advice for Minnesota Patients

Given the varied nature of glp1 coverage, patients in Minnesota are encouraged to carefully review their benefit documents and consult with HR representatives. Critical information to confirm includes details about coverage scope, expected copays, and whether prior authorization is necessary to gain access to GLP-1 medications for either diabetes or weight loss management.

Outlook: Striving for Affordable, Effective Solutions

As the conversation around weight management and diabetes care continues, Minnesota employers remain at a crossroads, seeking ways to strike a balance between clinical benefit and affordability. With employer health plans regularly reevaluating their pharmacy benefits strategies and experimenting with new pricing models, disparities in GLP-1 prescription access are expected to persist in the near future. The question of how best to ensure equitable and sustainable glp1 coverage will likely stay at the forefront for Minnesota businesses and their employees alike.